Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The main factor was an increase in net sales and operating profit in the clinical laboratory testing business. In that business, the company promoted an increase in the number of tests handled, optimization of selling prices, strengthening of its sample collection system, and greater efficiency in testing operations. The pharmacy business was affected by a decline in the number of prescriptions filled due to a decrease in the number of stores and other factors, as well as fluctuations in drug purchase prices following the revision of drug prices. The ICT business was affected by increases in personnel, selling and development costs.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥11,003 million (YoY +0.7%) |
| Operating profit | ¥546 million (YoY +19.9%) |
| Ordinary income | ¥637 million (YoY +18.8%) |
| Profit attributable to owners of the parent | ¥385 million (YoY +20.2%) |
| Net income per share | ¥38.58 |
| Equity ratio | End of the current fiscal period 68.2 / End of previous period 70 |
| Total assets | ¥37,127 million |
| Net assets | ¥25,383 million |
| Full-year earnings forecast | Net Sales ¥44,300 million (YoY +1.7%) / Operating profit ¥2,700 million (YoY +8.1%) / Ordinary income ¥2,850 million (YoY +6.0%) / Net income ¥2,020 million (YoY +0.2%) |
| Annual Dividend Forecast | ¥125 → ¥128（+2.4%） |
| Segment revenue | Clinical Testing Business ¥6,939 million (YoY +1.1%), Dispensing Pharmacy Business ¥3,694 million (YoY -1.3%), ICT business ¥368 million (YoY +15.5%) |
| Segment profit | Clinical Testing Business ¥551 million (YoY +11.0%), Dispensing Pharmacy Business ¥27 million (YoY -10.1%), ICT business ¥63 million (YoY -19.1%) |
| Depreciation and amortization | ¥269 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥0 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥0 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | No (no companies newly consolidated or excluded) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 10,680,177 Shares |
| Treasury Shares at Period-End | 708,309 Shares |
| Factors Behind Changes in Business Performance | The main factor was an increase in net sales and operating profit in the clinical laboratory testing business. In that business, the company promoted an increase in the number of tests handled, optimization of selling prices, strengthening of its sample collection system, and greater efficiency in testing operations. The pharmacy business was affected by a decline in the number of prescriptions filled due to a decrease in the number of stores and other factors, as well as fluctuations in drug purchase prices following the revision of drug prices. The ICT business was affected by increases in personnel, selling and development costs. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was mainly due to increases in net sales and operating profit in the clinical laboratory testing business. In that business, the company worked to increase the number of tests handled, optimize selling prices, strengthen its sample collection system through the use of information technology, and improve the efficiency of testing operations.